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Background: Toxoplasmosis, caused by an obligate intracellular protozoan parasite Toxoplasma gondii, has been a
serious clinical and veterinary problem. Effective DNA vaccines against T. gondii can prevent and control the spread
of toxoplasmosis, which is important for both human health and the farming industry. The T. gondii 14-3-3 protein
has been proved to be antigenic and immunogenic and was a potential vaccine candidate against toxoplasmosis.
In this study, we evaluated the immune responses induced by recombinant plasmids encoding T. gondii surface
antigen 1 (SAG1) and 14-3-3 protein by immunizing BALB/c mice intramuscularly.
Methods: In the present study, BALB/c mice were randomly divided into five groups, including three experimental
groups (pSAG1, p14-3-3 and pSAG1/14-3-3) and two control groups (PBS and pBudCE4.1), and were immunized
intramuscularly three times. The levels of IgG antibodies and cytokine production in mouse sera were determined
by enzyme-linked immunosorbent assays (ELISA). Two weeks after the last immunization, all mice were challenged
intraperitoneally (i.p.) with 1×104 tachyzoites of T. gondii and the survival time of mice was observed and recorded
every day.
Results: Mice vaccinated with pSAG1, p14-3-3 or pSAG1/14-3-3 developed high levels of IgG2a and gamma
interferon (IFN-γ) and low levels of interleukin-4 (IL-4) and interleukin-10 (IL-10) compared to control groups
(PBS or pBudCE4.1), which suggested a modulated Th1 type immune response (P<0.05). After intraperitoneal
challenge with 1×104 tachyzoites of T. gondii (RH strain), the survival time of mice in experimental groups was
longer than control groups (P<0.05). Mouse immunized with pSAG1/14-3-3 induced a higher level of IgG antibody
response and significantly prolonged the survival time when compared with pSAG1 or p14-3-3 (P<0.05).
Conclusions: The study suggested that T. gondii 14-3-3 protein can induce effective immune responses in BALB/c
mice and was a novel DNA vaccine candidate against toxoplasmosis, and the immune protective efficacy elicited
by SAG1 gene was also demonstrated. Our results also showed multi-gene vaccine significantly enhanced immune
responses and protective efficacy and was superior to the single-gene vaccine.
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Toxoplasma gondii is a crescent shaped intracellular
protozoan parasite that lives in various tissues of humans
and other warm-blooded animals, causing toxoplasmosis
[1]. Its life cycle is complex, including the sexual stage
and the asexual stage; the sexual stage produces infective
oocysts only in felines, whereas the asexual stage occurs
in all infected animals and produces tachyzoites (the pro-
liferative stage) and eventually, bradyzoites or zoitocysts
(latent tissue cysts) [2,3]. There are three different infec-
tious stages in the life cycle of T. gondii, i.e. tachyzoites,
bradyzoites contained in tissue cysts and sporozoites
inside sporulated oocysts, which are infectious for both
intermediate and definitive hosts [4]. Epidemiological
survey suggested that there was a wide distribution
and high prevalence of T. gondii in many areas of the
world and up to one third of the world’s population
was infected [5-7]. In immunocompetent individuals,
T. gondii infection is usually asymptomatic or solely
causes mild symptoms; however, T. gondii can result in
severe disease, such as ocular toxoplasmosis and enceph-
alitis in immunocompromised patients and congenital
birth defects [8,9]. Toxoplasmosis has been an important
public health concern in some countries, especially in
tropical countries, which leads to significant economic
loss in human health and the farming industry [10].
Currently chemotherapy (a variety of antibiotics) is the
primary strategy in the treatment of the acute phase of
the disease and cannot act against chronic infection [11].
Due to adverse reactions and drug-resistance of T. gondii
anti-parasitic drugs, there is an urgent need to develop
effective measures for the control of T. gondii. Vaccin-
ation protocol has distinct advantages over chemotherapy
and theoretically a single treatment can produce life-long
protection; Therefore, there is a strong desire to develop
vaccines against T. gondii [12]. During the past decade,
anti-T. gondii vaccines have experienced different phases,
containing live vaccines, attenuated-live vaccines, killed
vaccines and subunit vaccines [13]. There is only a com-
mercial vaccine for sheep, Toxovax, which is made of the
live tachyzoites of strain S48, while there are none for
humans [14-16]. In recent years, DNA vaccines against
T. gondii have been well developed and received con-
siderable attention and are an good option for this ubi-
quitous parasite [17]. A large number of experimental
studies have shown DNA vaccines can elicit a predom-
inantly Th1 immune response against toxoplasmosis in
vaccinated mice; Furthermore, the DNA vaccines have
the particular capacity to induce CD4+ T-lymphocyte and
CD8+ cytotoxic T-lymphocyte (CTL) responses against
the specialized antigen [18,19]. Proteins involved in the
process of invasion of the host cell by T. gondii are
regarded as the key candidate antigens in the design of
the DNA vaccines. Thus, it is possible and promising todevelop a safe and effective vaccine against human and
animal toxoplasmosis.
14-3-3 proteins are a family of high sequence con-
servation and are present in all eukaryotic organisms,
including plants, yeasts, protozoans, worms, insects and
humans, which are involved in multiple pivotal bio-
logical regulatory processes, such as cell signal trans-
duction, neuronal development and apoptosis [20,21].
In T. gondii, 14-3-3 protein was first found in the feline
intraepithelial gametocyte stages [22]. Subsequently, it
was detected in tachyzoites of T. gondii and presented
in two different isoforms; The major isoform was cyto-
plasmic and to a lesser extent membrane-associated,
whereas the minor one was associated with the detergent-
resistant lipid rafts [23]. Meanwhile, the 14-3-3 protein
was shown to be present in the parasitophorous vacuole
(PV) of T. gondii tachyzoites and was proved to be a mem-
ber of excreted secreted antigens (ESA); The recombinant
14-3-3 protein was immunogenic and played a vital role
in stimulating the host immune system and the 14-3-3
protein was a potential vaccine candidate against toxo-
plasmosis [24]. In Schistosoma mansoni, it has been
confirmed that 14-3-3 protein can induce significant
humoral and cellular responses in mice, which provided
moderate but significant protection against challenge in-
fection [25]. However, the protective efficacy of 14-3-3
protein as a vaccine antigen against T. gondii remains
unclear.
Although vaccines against toxoplasmosis are of dif-
ferent types, the recombinant subunit DNA vaccine
has been promising with its strong immune responses in
animal models and remaining cost effectiveness [26]. A
range of studies suggested multi-antigenic DNA vaccines
could provide significant protection against toxoplas-
mosis and are better than a single-gene vaccine [27,28].
As a good vaccine candidate, the main surface antigen
of T. gondii tachyzoites, SAG1, is well described and is
able to induce both effective and durable humoral and
cellular immune responses in immunized mice [29-31].
In a word, SAG1 is a preferred antigen in constructing
multi-gene DNA vaccine and is also regarded as a refer-
ence as compared to other antigens.
In this study, we constructed three eukaryotic plasmids,
pBudCE4.1-SAG1, pBudCE4.1-14-3-3 and pBudCE4.1-
SAG1/14-3-3, to examine humoral and cellular im-
mune responses elicited by 14-3-3 and SAG1 protein
in BALB/c mice. The survival time of mice after infec-
tion with the highly virulent RH strain of T. gondii
was examined. The aim of this study was to evaluate
the potential of T. gondii 14-3-3 protein as a vaccine
candidate antigen, demonstrate the immune protective
efficacy elicited by SAG1 gene and compare the im-
munological effect between single-gene and multi-gene
vaccines.
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Animals and parasite
Six to eight week-old female Kunming and BALB/c mice
were purchased from Shandong University Laboratory
Animal Centre (Jinan, China) and maintained under a
standard specific-pathogen-free condition. In this study,
Kunming mice were used to maintain and passage
tachyzoites of T. gondii; BALB/c mice were used in the
immunization experiment. All the animal experiments
were approved by the Animal Ethics Committee of
Shandong University.
The tachyzoites of T. gondii (RH strain) were collected
from the peritoneal fluid of the infected Kunming mice.
The peritoneal fluid was washed by 0.01M phosphate
buffered saline (PBS) three times in a low speed centrifu-
gation and disrupted using an Ultrasonic disintegrator,
and then centrifuged at 2100×g for 15 min. The super-
natant containing soluble tachyzoite antigens (STAg)
was kept at −80°C until further use.
Plasmid construction
The total DNA (or RNA) of T. gondii was extracted from
purified tachyzoites according to the manufacturer's
protocol. The open reading frame (ORF) of SAG1 gene
[GenBank: S76248.1] and 14-3-3 gene [GenBank:
AB012775.1] was obtained from T. gondii DNA or cDNA
by PCR amplification using the following synthetic pri-
mers in which recognition sites were introduced and
underlined.








The PCR productions of SAG1 and 14-3-3 gene
were respectively inserted into the pEASY-T1 Vector
(TransGen, China) to generate two new prokaryotic plas-
mids. These recombinant plasmids were then transformed
into Escherichia coli DH5α. After purification, pEASY-T1/
SAG1 and pEASY-T1/14-3-3 were respectively double
digested with appropriate restriction enzymes (Sal I/Xba I
and Kpn I/Xho I) and purified from agarose gel. The
pBudCE4.1 co-expression vector (Invitrogen, USA) is
used to construct eukaryotic expression plasmids, which
contains two promoters and is designed for simultaneous
expression of two genes in mammalian cell lines. The
SAG1 gene was inserted into pBudCE4.1 plasmid under
the control of CMV promoter by the Sal I and Xba I
cloning sites. The 14-3-3 gene was inserted into the
Kpn I and Xho I sites of the EF-1α promoter in the
pBudCE4.1. To construct multi-gene plasmid, the twogenes were both inserted in pBudCE4.1 with appropriate
cloning sites. The new plasmids were named pSAG1,
p14-3-3 and pSAG1/14-3-3. The recombinant plasmids
were transformed into Escherichia coli TOP10; the
inserted genes were verified by PCR, restriction enzyme
analysis and double-stranded sequencing. All the plas-
mids were purified using an endotoxin-free plasmid puri-
fication kit (TIANGEN, China). The concentration of
purified plasmids was determined by spectrophotometer
at OD 260 and OD 280, and the ratios were 1.8-2.0.
Expression of recombinant plasmids in vitro
Hela cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, GIBCO) with 10% Fetal Bovine Serum
(FBS), 100mg/ml streptomycin and 100 IU/ml penicillin
at 37°C in 5% CO2. Before transfection, Hela cells were
transferred in a 6-well plate (Costar, USA). When the
density of hela cells reached 80%-90%, the recombinant
eukaryotic expression plasmids (pSAG1, p14-3-3 and
pSAG1/14-3-3) were transfected into cells using the
Lipofectamine 2000 regent (Invitrogen, USA) according
to the manufacturer’s guidance. The empty vector
pBudCE4.1 was also transfected into Hela cells as a con-
trol. Lipofectamine 2000 reagent was respectively mixed
with pSAG1, p14-3-3, pSAG1/14-3-3 and pBudCE4.1 at a
concentration of 10μg/ml in DMEM without Fetal Bovine
Serum (FBS) and antibiotics, and was incubated at room
temperature for 20 min. The mixture of lipofectin and
plasmid DNA was then added into Hela cells. The cells
were incubated with the transfection mix for 6h at 37°C in
the 5% CO2. At the end of incubation, fresh medium was
supplemented and plates were returned to the cell incuba-
tor for further incubation. After 48h of transfection, Hela
cells were collected and expression of the genes was evalu-
ated by RT-PCR and Western blotting analysis.
Total RNA was extracted from the transfected Hela
cells using Trizol Up (TransGen, China) and the mRNA
transcription level of genes was identified by RT-PCR
using specific primers of the inserted genes. RT-PCR pro-
ducts were then analyzed by agarose gel electrophoresis.
In addition, the transfected cells were treated on ice
with RIPA Lyses Buffer (50mM Tris pH 7.4, 150mM
NaCl, 1% Triton X-100, 1% Sodium deoxycholate, 0.1%
SDS) containing 1mM protease inhibitor PMSF (phenyl-
methanesulfonyl fluoride) and centrifuged at 13,000×g for
5 min. The translation of genes in Hela cells was detected
by Western blotting with anti-T. gondii polyclonal anti-
body (Goat) and a HRP (horseradish peroxides)-labeled
rabbit anti-goat IgG antibody (Sigma, USA) as a secondary
antibody. The conjugated substrate was detected using 3,
3’-Diaminobenzidine tetrahydrochloride reagent (Sigma,
USA) as described previously [32,33] and pre-stained
protein marker (Fermentas, Canada) was used as mo-
lecular mass standards.
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To observe the immunogenicity of recombinant plas-
mids, BALB/c mice were randomly divided into five
groups (12/group). Before vaccination, plasmids were
diluted and suspended in sterile phosphate buffered
saline (PBS) to a final concentration of 1μg/μl. All ex-
perimental groups were injected intramuscularly (i.m.)
three times at weeks 0, 2 and 4 with plasmid DNA
(100μg/each). Control groups received PBS (100μl/each)
or empty plasmid (100μg/each). Blood samples of mice
were collected from the tail vein plexus on the day before
each vaccination and the sera were obtained and stored
at −20°C for ELISA. Two weeks after the last injection,
the mice in five groups were challenged intraperitoneally
(i.p.) with 1×104 tachyzoites of T. gondii RH strain as
previously described [34] and the survival time of mice
was observed and recorded every day.
Determination of antibodies by ELISA
The levels of antibodies in mouse sera were determined
by enzyme-linked immunosorbent assays (ELISA) as
previously described [35]. Briefly, the microtiter plates
(Costar, USA) were coated with 1μg STAg in 50mM car-
bonate buffer (pH 9.6) and incubated at 4°C overnight.
After three washes, the plates were blocked with 1%
Bovine Serum Albumin (BSA) for 1 h at 37°C and subse-
quently incubated with the mouse sera diluted in PBS
for 1 h at 37°C. HRP-conjugated goat anti-mouse IgG,
IgG1 or IgG2a (Sigma, USA) were used as the secondary
antibody to detect bound antibodies. Finally, immune
complexes were revealed by incubating with orthophe-
nylene diamine (Sigma, USA) and 0.15% H2O2 for
30 min. The reaction was stopped by adding 2M H2SO4,
and the absorbance was measured at 490 nm with an
ELISA reader. All samples were run in triplicate.
Cytokine assays
The levels of cytokines were detected according to the
method described previously [36]. Two weeks after the
final immunization, three mice per group were killed
and the spleen was separated in a sterile condition. The
spleen cells were cultured in 96-well plates at 37°C in
5% CO2 and cell-free supernatants were harvested and
assayed for interleukin-4 (IL-4) at 24h, for interleukin-10
(IL-10) at 72h, gamma interferon (IFN-γ) at 96h using a
commercial ELISA Kit (R&D Systems, USA) following
the procedure recommended by the manufacturer.
Statistical analysis
Statistical analysis in all groups was performed using SPSS
software. The levels of cytokine and antibody production
among different groups were analyzed and determined
by one-way ANOVA. Survival time for the experimental
and control mice was compared using the Kaplan-Meiermethod. The difference was considered statistically sig-
nificant if P value was less than 0.05.
Results
Identification of the eukaryotic expression plasmids
The SAG1 and 14-3-3 genes were cloned into the
eukaryotic expression vector pBudCE4.1 through appro-
priate restriction enzymes to form three different plasmids
(Figure 1A, B&C). To ensure the fidelity of plasmids, they
were detected by PCR and restriction enzyme analysis,
and confirmed by sequencing in both directions. The
result of restriction enzyme digestion of plasmids is shown
in Figure 1D.
Gene expression in Hela cells
Hela cells were transfected with pSAG1, p14-3-3 or
pSAG1/14-3-3 for 48h, the level of mRNA and gene
expression was evaluated by RT-PCR and Western
blotting, respectively. Electrophoresis of RT-PCR pro-
ducts from transfected Hela cells showed the expected
fragment of the SAG1 gene (1011bp) or 14-3-3 gene
(801bp) (Figure 2A&B), which indicated that the tran-
scriptional expression of the constructs was successful
in vitro. In the Western blotting analysis (Figure 2C),
the expression of SAG1 gene (about 30kDa) and 14-3-3
protein (about 36kDa) was respectively detected in Hela
cells transfected with pSAG1 or p14-3-3; These two kinds
of protein were both detected in cells transfected with
pSAG1/14-3-3, whereas the empty vector transfected
cells did not show any band. The results indicated that
SAG1 and 14-3-3 proteins were successfully expressed
and secreted by Hela cells and possessed immunological
activity.
Antibody responses in immunized BALB/c mice
The levels of IgG antibodies induced by recombinant
plasmids in mice were detected post immunization by
ELISA at weeks 0, 2, 4 and 6. As shown in Figure 3,
significantly high levels of IgG antibodies were observed
in the experimental group vaccinated with pSAG1,
p14-3-3 or pSAG1/14-3-3 and the levels of antibodies
gradually increased with successive immunization, which
were higher than those of the control groups with PBS or
pBudCE4.1. There was significant difference between the
experimental groups and the control groups (P<0.05).
The level of IgG antibody in pSAG1/14-3-3 group was
higher than those of pSAG1 or p14-3-3 group (P<0.05).
However, there was no statistical difference between the
pSAG1 group and the p14-3-3 group (P>0.05). These
results indicated that a recombinant plasmid encoding
T. gondii 14-3-3 protein induced a strong IgG antibody
response in mice, and OD value reached a high level
two weeks after the third immunization.
Figure 1 Constructed plasmid maps and identification of the recombinant plasmids with restriction enzyme digestion. (A) The SAG1
gene was inserted into pBudCE4.1 plasmid by the Sal I and Xba I cloning sites. (B) The 14-3-3 gene was inserted with the Kpn I and Xho I sites.
(C) The two genes were both inserted in pBudCE4.1 with appropriate cloning sites. (D) DNA Mark (lane M), pSAG1 digested with Sal I (lane 1),
pSAG1 digested with Sal I/Xba I (lane 2), p14-3-3 digested with Kpn I (lane 3), p14-3-3 digested with Kpn I/Xho I (lane 4), pSAG1/14-3-3 digested
with Sal I /Xba I (lane 5), pSAG1/14-3-3 digested with Kpn I/Xho I (lane 6).
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groups at the second week after the final immunization
were analyzed to determine whether a Th1 or Th2 re-
sponse was elicited and the results are shown in Figure 4.
An apparent predominance of IgG2a over IgG1 was
observed in single-gene or multi-gene vaccine immu-
nized mice (pSAG1, p14-3-3 or pSAG1/14-3-3), which
indicated a shift toward the Th1 type response. Further-
more, mice immunized with pSAG1/14-3-3 generated
higher levels of IgG2a than with pSAG1 or p14-3-3
(P<0.05). However, there was no significant difference in
IgG2a levels between the groups immunized with pSAG1
and p14-3-3 (P>0.05). The data showed that vaccination
with p14-3-3 in mice generated a Th1 immune response.
Cytokine production
The supernatant of splenocytes was harvested at differ-
ent times and used to measure the amounts of cytokine
production (IFN-γ, IL-4 and IL-10) in different groups.
As shown in Table 1, mice vaccinated with pSAG1/14-3-3 generated significantly higher levels of IFN-γ
as compared to mice with single-gene plasmids, PBS or
empty vector (P<0.05). The level of IFN-γ in pSAG1
immunized mice was higher than the p14-3-3, but there
was no significant statistical difference between the two
groups (P>0.05). Meanwhile, the low levels of IL-4 and
IL-10 in the experiment and control groups suggested
that there was no statistical difference among all the
groups (P>0.05). Generally, IFN-γ and IL-2 favor Th1 type
immune responses, whereas IL-4 and IL-10 favor the Th2
type [37]. With this knowledge, these results confirmed
that the cellular immune response induced by single-gene
or multi-gene vaccines ((pSAG1, p14-3-3 or pSAG1/
14-3-3)) was inclined to a Th1 type response in mice.
Survival time analysis against a lethal challenge
in BALB/c mice
To evaluate the immunoprotection induced by the DNA
vaccines (single or multiple gene), all the mice were
challenged intraperitoneally (i.p.) with 1×104 tachyzoites
Figure 2 In vitro expression analysis of the constructs in Hela cells by RT-PCR and Western blotting. (A) RT-PCR results for SAG1 and
14-3-3 (lane1 and lane 2) in cells transfected with pSAG1 or p14-3-3. (B) RT-PCR results for SAG1 and 14-3-3 (lane1 and lane 2) in cells transfected
with pSAG1/14-3-3. (C) Pre-stained protein marker (lane M), hela cells transfected with pSAG1 (lane 1), cells transfected with p14-3-3 (lane 2), cells
transfected with pSAG1/14-3-3 (lane 3).
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until all mice died. Survival percentage of mice in differ-
ent groups is shown in Figure 5. Immunization of mice
with the DNA vaccines (pSAG1, p14-3-3 and pSAG1/
14-3-3) dramatically increased the survival time in
comparison with the control groups vaccinated with PBS
or pBudCE4.1 (P<0.05). Mice vaccinated with pSAG1/
14-3-3 showed an increased survival time (11.5±3.5 days)
compared to pSAG1 group (7.7±2.5 days) or p14-3-3
group (6.8±2.6 days) (P<0.05). However, no significant
difference was observed between the groups of mice
immunized with pSAG1 and p14-3-3 (P>0.05). All the
experimental mice could not resist lethal acute T. gondii
infections and died, which indicated that the DNA
vaccine did not provide complete protection against
T. gondii.
Discussion
The present study showed that all mice in the experi-
mental groups injected with pSAG1, p14-3-3 or pSAG1/
14-3-3 induced the Th1 mediated immune responses,
defined by high levels of IgG2a and IFN-γ, and low levels
of IL-4 and IL-10. Significantly higher levels of IgG2a
and IFN-γ were observed in mice immunized withpSAG1, p14-3-3 or pSAG1/14-3-3 as compared to
those of controls and this increased with successive
immunization. IFN-γ is the key mediator of resistance to
T. gondii and promotes multiple complex intracellular
mechanisms to kill the parasite and inhibit its replication
[38]. Moreover, IFN-γ plays an important role in pro-
tecting hosts during both acute and chronic phases of
toxoplasmosis [39,40]. Although IFN-γ is essential for
long-term resistance to T. gondii, its overproduction can
also induce severe immunopathology in animal models.
It was reported that genetically susceptible C57BL/6 mice
developed necrosis of the villi and mucosal cells in small
intestines following peroral infection with T. gondii and
that IFN-γ-mediated pathology in the small intestine pre-
disposes to death in these mice; In contrast, IFN-γ was
required for survival in infected genetically resistant
BALB/c mice [41]. It appears that overproduction of
IFN-γ occurs in the genetically susceptible mice follow-
ing T. gondii infection and contributes to early death
of these mice [41,42]. Thus, constructed DNA vaccines
generated not only the protective effects but also pos-
sible severe immunopathology in animal models. When
we evaluated the protective effect of vaccines in the
genetically susceptible mice, mortality in mice caused
Figure 3 Measurement of specific IgG antibodies in sera of immunized mice. Sera were collected one day prior to each immunization and
determined by ELISA. Results are shown as means of OD 490±SD and statistical differences (P<0.05) are indicated by * compared with PBS or
pBudCE4.1.
Figure 4 Distribution of IgG subtypes IgG1 and IgG2a in immunized mice. The levels of IgG subtypes IgG1 and IgG2a in sera of mice 2
weeks after the last immunization were analyzed by ELISA. Results are expressed as means of the OD_490±SD and statistically significant
differences (P < 0.05) are indicated by an asterisk (*) as compared to control groups.
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Table 1 Cytokine production by splenocytea cultures
from immunized BALB/c mice
Group Production of cytokine(pg/ml)b
IFN-γ IL-4 IL-10
PBS 50.41±2.20 39.15±2.65 46.43±2.93
pBudCE4.1 50.80±1.75 35.68±2.88 40.87±2.82
pSAG1 698.14±88.65* 35.31±3.48 36.90±1.17
p14-3-3 605.53±108.83* 34.68±3.34 37.74±2.20
pSAG1/14-3-3 1188.23±169.15*# 38.83±3.02 37.23±1.33
a Splenocytes from 3 mice per group two weeks after the final immunization.
b Values for IFN-γ at 96h, IL-4 at 24h, IL-10 at 72h are expressed as mean ± SD.
* Compared with PBS or pBudCE4.1 group, P< 0.05; #: compared with pSAG1
or p14-3-3, P<0.05.
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of DNA vaccines, potential immunopathology generated
by proinflammatory mediators including IL-12, IL-18,
IFN-γ, TNF-α and NO should be carefully considered.
Prolonged survival time after intraperitoneally chal-
lenge with 1×104 tachyzoites of the virulent RH T. gondii
in immunized BALB/c mice was observed in this study,
as compared to the control groups. However, on the 18th
day after challenge all mice were dead and constructed
DNA vaccines only provided partial protection. The data
also showed that mice immunized with pSAG1/14-3-3
induced a stronger humoral and cellular immune re-
sponse and significantly prolonged survival time when
compared with pSAG1 or p14-3-3 group. Our results
described above are consistent with previous studies
showing that mice immunized with a plasmid encoding
the SAG1 gene gave effective protection against T. gondii
infection [29,43]. The major limitation of the current


























Figure 5 Survival curves of vaccinated BALB/c mice against T.
gondii infection. The mice in five groups were challenged with
1×104 tachyzoites of virulent T. gondii RH strain 2 weeks after the
last immunization. Each group was composed of seven mice.
Survival was monitored daily for 18 days after challenge.in BALB/c mice. Preventing tissue cyst formation in ani-
mals for consumption can help avoid parasite transmis-
sion to humans and animals, which is important in the
farming industry [12]. Experimental studies showed that
DNA vaccination can induce both survival prolongation
and brain cyst reduction in rodents [44,45]. An effective
and safe vaccine should protect the hosts against T. gondii
infection and reduce the potential risk of tissue cyst gen-
eration in intermediate hosts and development of oocysts
in cats.
Protective immunity to T. gondii is complex and
involves lots of elements of the host immune system,
furthermore, it is recognized that this infection in im-
munocompetent hosts elicits a strong Th1 type immunity
response, which is characterized by the generation of para-
site specific CD4+ and CD8+ T cells that produce IFN-γ
and provide protective immunity against T. gondii [46,47].
Successful DNA vaccination is in theory well suited to
stimulate effector mechanisms depending on antigen
presentation along with major histocompatibility com-
plex class 1 (MHC-1) molecules, which stimulate CD8+
cytotoxic T cells [29,48]. In recent years, most study
results have indicated that several parameters affect the
immune response generated by the DNA vaccine, and in
the design of DNA vaccines the candidate antigen and
the eukaryotic expression vector were of great concern.
Good vaccine candidates should induce protective cel-
lular Th1 and humoral Th2 responses as well, both at
the level of intestinal mucosa (local) and whole organism
(systemic) [12]. In the present study, the SAG1 and 14-3-3
protein were selected due to their potential to elicit an
immune response, our results also confirmed that SAG1
has been a prime antigen because of its immunodomi-
nance and 14-3-3 protein is a novel candidate antigen.
In the meantime, the pBudCE4.1 co-expression vector is
used to construct the DNA vaccines and contains two
promoters for high-level, constitutive, independent ex-
pression of two recombinant proteins, which is a good
choice for the construction of multi-gene vaccine.
Conclusions
This study suggested that T. gondii 14-3-3 protein can
induce humoral and cellular immune responses and was
a novel DNA vaccine candidate against toxoplasmosis.
The results also indicated that multi-gene vaccines sig-
nificantly enhanced immune responses and protective
efficacy and were superior to the single-gene vaccine.
However, no effective vaccine that provided complete
protection against a lethal challenge with RH tachyzoites
was demonstrated, but DNA vaccines are still considered
a good strategy in the control of T. gondii. A combination
of different antigens in a single formulation should be
considered and valued to design an effective and durable
vaccine against toxoplasmosis. Future research should
Meng et al. Parasites & Vectors 2012, 5:273 Page 9 of 10
http://www.parasitesandvectors.com/content/5/1/273mainly focus on multi-gene vaccines, and SAG1 gene is
one of the best choices and 14-3-3 protein is promising.
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